Life-threatening rituximab-induced pyoderma gangrenosum successfully treated with intravenous immunoglobulin.

The article describes the case of a 29-year-old woman with life-threatening rituximab-induced pyoderma gangrenosum. The patient had a history of proteinase-3-anti-neutrophil cytoplasmic antibody (PR3-ANCA)-positive granulomatosis with polyangiitis (GPA). She experienced symptoms of septic peritonitis, copious vaginal discharge, and more extensive vulvovaginal ulceration. Her illness was successfully treated with intravenous immunoglobulin.